Item 5.02 Departure of Directors or Principal Officers; Election of Directors;


          Appointment of Principal Officers; Compensatory Arrangements of Certain
          Officers.

On October 24, 2021, Jed A. Latkin resigned as Chief Executive Officer, Chief Financial Officer and Chief Operating Officer of Navidea Biopharmaceuticals, Inc. (the "Company"), and as a member of the Company's Board of Directors (the "Board"), effective immediately.

An Office of the CEO including three members of the Company's Board of Directors has been established to lead the Company on an interim basis while the next Chief Executive Officer of the Company is identified with the assistance of an executive search firm. The Office of the CEO consists of three Board Members, including the Chairman, Vice Chairman and Thomas Farb, and the Company's Senior Vice President and Chief Medical Officer, Michael Rosol, Ph.D., and the Company's Vice President of Finance and Administration, Erika Eves.

A copy of the Company's press release dated October 26, 2021 is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.



            (a)    Not applicable.

            (b)    Not applicable.

            (c)    Not applicable.

            (d)    Exhibits

Exhibit No. Description



99.1          Press release dated October 26, 2021

104         Cover Page Interactive Data File (embedded within the Inline XBRL document)



                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses